Assessment of outcomes and novel immune biomarkers in metaplastic breast cancer: a single institution retrospective study
Abstract Background Metaplastic breast cancer remains poorly characterized given its rarity and heterogeneity. The majority of metaplastic breast cancers demonstrate a phenotype of triple-negative breast cancer; however, differences in clinical outcomes between metaplastic breast cancer and triple-n...
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2020-01-01
|
| Series: | World Journal of Surgical Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12957-019-1780-8 |
| _version_ | 1811270828953698304 |
|---|---|
| author | Evan Morgan Anupama Suresh Akaansha Ganju Daniel G. Stover Robert Wesolowski Sagar Sardesai Anne Noonan Raquel Reinbolt Jeffrey VanDeusen Nicole Williams Mathew A. Cherian Zaibo Li Gregory Young Marilly Palettas Julie Stephens Joseph Liu Amanda Luff Bhuvaneswari Ramaswamy Maryam Lustberg |
| author_facet | Evan Morgan Anupama Suresh Akaansha Ganju Daniel G. Stover Robert Wesolowski Sagar Sardesai Anne Noonan Raquel Reinbolt Jeffrey VanDeusen Nicole Williams Mathew A. Cherian Zaibo Li Gregory Young Marilly Palettas Julie Stephens Joseph Liu Amanda Luff Bhuvaneswari Ramaswamy Maryam Lustberg |
| author_sort | Evan Morgan |
| collection | DOAJ |
| description | Abstract Background Metaplastic breast cancer remains poorly characterized given its rarity and heterogeneity. The majority of metaplastic breast cancers demonstrate a phenotype of triple-negative breast cancer; however, differences in clinical outcomes between metaplastic breast cancer and triple-negative breast cancer in the era of third-generation chemotherapy remain unclear. Methods We compared the clinical outcomes between women with metaplastic breast cancer and women with triple-negative breast cancer diagnosed between 1994 and 2014. Metaplastic breast cancer patients were matched 1:3 to triple-negative breast cancer patients by stage and age at diagnosis. Distant disease-free survival (DDFS) and overall survival (OS) were estimated using Kaplan Meier methods and Cox proportional hazard regression models. Immune checkpoint markers were characterized by immunohistochemistry in a subset of samples. Results Forty-four metaplastic breast cancer patients (stage I 14%; stage II 73%; stage III 11%; stage IV 2%) with an average age of 55.4 (± 13.9) years at diagnosis. Median follow-up for the included metaplastic breast cancer and triple-negative breast cancer patients (n = 174) was 2.8 (0.1–19.0) years. The DDFS and OS between matched metaplastic breast cancer and triple-negative breast cancer patients were similar, even when adjusting for clinical covariates (DDFS: HR = 1.64, p = 0.22; OS: HR = 1.64, p = 0.26). Metaplastic breast cancer samples (n = 27) demonstrated greater amount of CD163 in the stroma (p = 0.05) and PD-L1 in the tumor (p = 0.01) than triple-negative breast cancer samples (n = 119), although more triple-negative breast cancer samples were positive for CD8 in the tumor than metaplastic breast cancer samples (p = 0.02). Conclusions Patients with metaplastic breast cancer had similar outcomes to those with triple-negative breast cancer based on DDFS and OS. The immune checkpoint marker profile of metaplastic breast cancers in this study may prove useful in future studies attempting to demonstrate an association between immune profile and survival. |
| first_indexed | 2024-04-12T22:09:09Z |
| format | Article |
| id | doaj.art-e6d5b8609f874318bf2d21e78b823ce7 |
| institution | Directory Open Access Journal |
| issn | 1477-7819 |
| language | English |
| last_indexed | 2024-04-12T22:09:09Z |
| publishDate | 2020-01-01 |
| publisher | BMC |
| record_format | Article |
| series | World Journal of Surgical Oncology |
| spelling | doaj.art-e6d5b8609f874318bf2d21e78b823ce72022-12-22T03:14:50ZengBMCWorld Journal of Surgical Oncology1477-78192020-01-0118111210.1186/s12957-019-1780-8Assessment of outcomes and novel immune biomarkers in metaplastic breast cancer: a single institution retrospective studyEvan Morgan0Anupama Suresh1Akaansha Ganju2Daniel G. Stover3Robert Wesolowski4Sagar Sardesai5Anne Noonan6Raquel Reinbolt7Jeffrey VanDeusen8Nicole Williams9Mathew A. Cherian10Zaibo Li11Gregory Young12Marilly Palettas13Julie Stephens14Joseph Liu15Amanda Luff16Bhuvaneswari Ramaswamy17Maryam Lustberg18Stefanie Spielman Comprehensive Breast Cancer, The Ohio State UniversityStefanie Spielman Comprehensive Breast Cancer, The Ohio State UniversityDepartment of Internal Medicine, Riverside Methodist HospitalStefanie Spielman Comprehensive Breast Cancer, The Ohio State UniversityStefanie Spielman Comprehensive Breast Cancer, The Ohio State UniversityStefanie Spielman Comprehensive Breast Cancer, The Ohio State UniversityStefanie Spielman Comprehensive Breast Cancer, The Ohio State UniversityStefanie Spielman Comprehensive Breast Cancer, The Ohio State UniversityStefanie Spielman Comprehensive Breast Cancer, The Ohio State UniversityStefanie Spielman Comprehensive Breast Cancer, The Ohio State UniversityStefanie Spielman Comprehensive Breast Cancer, The Ohio State UniversityDepartment of Pathology, The Ohio State University Medical CenterCenter for Biostatistics, Department of Biomedical Informatics, The Ohio State UniversityCenter for Biostatistics, Department of Biomedical Informatics, The Ohio State UniversityCenter for Biostatistics, Department of Biomedical Informatics, The Ohio State UniversityStefanie Spielman Comprehensive Breast Cancer, The Ohio State UniversityStefanie Spielman Comprehensive Breast Cancer, The Ohio State UniversityStefanie Spielman Comprehensive Breast Cancer, The Ohio State UniversityStefanie Spielman Comprehensive Breast Cancer, The Ohio State UniversityAbstract Background Metaplastic breast cancer remains poorly characterized given its rarity and heterogeneity. The majority of metaplastic breast cancers demonstrate a phenotype of triple-negative breast cancer; however, differences in clinical outcomes between metaplastic breast cancer and triple-negative breast cancer in the era of third-generation chemotherapy remain unclear. Methods We compared the clinical outcomes between women with metaplastic breast cancer and women with triple-negative breast cancer diagnosed between 1994 and 2014. Metaplastic breast cancer patients were matched 1:3 to triple-negative breast cancer patients by stage and age at diagnosis. Distant disease-free survival (DDFS) and overall survival (OS) were estimated using Kaplan Meier methods and Cox proportional hazard regression models. Immune checkpoint markers were characterized by immunohistochemistry in a subset of samples. Results Forty-four metaplastic breast cancer patients (stage I 14%; stage II 73%; stage III 11%; stage IV 2%) with an average age of 55.4 (± 13.9) years at diagnosis. Median follow-up for the included metaplastic breast cancer and triple-negative breast cancer patients (n = 174) was 2.8 (0.1–19.0) years. The DDFS and OS between matched metaplastic breast cancer and triple-negative breast cancer patients were similar, even when adjusting for clinical covariates (DDFS: HR = 1.64, p = 0.22; OS: HR = 1.64, p = 0.26). Metaplastic breast cancer samples (n = 27) demonstrated greater amount of CD163 in the stroma (p = 0.05) and PD-L1 in the tumor (p = 0.01) than triple-negative breast cancer samples (n = 119), although more triple-negative breast cancer samples were positive for CD8 in the tumor than metaplastic breast cancer samples (p = 0.02). Conclusions Patients with metaplastic breast cancer had similar outcomes to those with triple-negative breast cancer based on DDFS and OS. The immune checkpoint marker profile of metaplastic breast cancers in this study may prove useful in future studies attempting to demonstrate an association between immune profile and survival.https://doi.org/10.1186/s12957-019-1780-8Metaplastic breast cancerClinical outcomesDistant disease-free survivalOverall survivalTriple-negative breast cancerImmune markers |
| spellingShingle | Evan Morgan Anupama Suresh Akaansha Ganju Daniel G. Stover Robert Wesolowski Sagar Sardesai Anne Noonan Raquel Reinbolt Jeffrey VanDeusen Nicole Williams Mathew A. Cherian Zaibo Li Gregory Young Marilly Palettas Julie Stephens Joseph Liu Amanda Luff Bhuvaneswari Ramaswamy Maryam Lustberg Assessment of outcomes and novel immune biomarkers in metaplastic breast cancer: a single institution retrospective study World Journal of Surgical Oncology Metaplastic breast cancer Clinical outcomes Distant disease-free survival Overall survival Triple-negative breast cancer Immune markers |
| title | Assessment of outcomes and novel immune biomarkers in metaplastic breast cancer: a single institution retrospective study |
| title_full | Assessment of outcomes and novel immune biomarkers in metaplastic breast cancer: a single institution retrospective study |
| title_fullStr | Assessment of outcomes and novel immune biomarkers in metaplastic breast cancer: a single institution retrospective study |
| title_full_unstemmed | Assessment of outcomes and novel immune biomarkers in metaplastic breast cancer: a single institution retrospective study |
| title_short | Assessment of outcomes and novel immune biomarkers in metaplastic breast cancer: a single institution retrospective study |
| title_sort | assessment of outcomes and novel immune biomarkers in metaplastic breast cancer a single institution retrospective study |
| topic | Metaplastic breast cancer Clinical outcomes Distant disease-free survival Overall survival Triple-negative breast cancer Immune markers |
| url | https://doi.org/10.1186/s12957-019-1780-8 |
| work_keys_str_mv | AT evanmorgan assessmentofoutcomesandnovelimmunebiomarkersinmetaplasticbreastcancerasingleinstitutionretrospectivestudy AT anupamasuresh assessmentofoutcomesandnovelimmunebiomarkersinmetaplasticbreastcancerasingleinstitutionretrospectivestudy AT akaanshaganju assessmentofoutcomesandnovelimmunebiomarkersinmetaplasticbreastcancerasingleinstitutionretrospectivestudy AT danielgstover assessmentofoutcomesandnovelimmunebiomarkersinmetaplasticbreastcancerasingleinstitutionretrospectivestudy AT robertwesolowski assessmentofoutcomesandnovelimmunebiomarkersinmetaplasticbreastcancerasingleinstitutionretrospectivestudy AT sagarsardesai assessmentofoutcomesandnovelimmunebiomarkersinmetaplasticbreastcancerasingleinstitutionretrospectivestudy AT annenoonan assessmentofoutcomesandnovelimmunebiomarkersinmetaplasticbreastcancerasingleinstitutionretrospectivestudy AT raquelreinbolt assessmentofoutcomesandnovelimmunebiomarkersinmetaplasticbreastcancerasingleinstitutionretrospectivestudy AT jeffreyvandeusen assessmentofoutcomesandnovelimmunebiomarkersinmetaplasticbreastcancerasingleinstitutionretrospectivestudy AT nicolewilliams assessmentofoutcomesandnovelimmunebiomarkersinmetaplasticbreastcancerasingleinstitutionretrospectivestudy AT mathewacherian assessmentofoutcomesandnovelimmunebiomarkersinmetaplasticbreastcancerasingleinstitutionretrospectivestudy AT zaiboli assessmentofoutcomesandnovelimmunebiomarkersinmetaplasticbreastcancerasingleinstitutionretrospectivestudy AT gregoryyoung assessmentofoutcomesandnovelimmunebiomarkersinmetaplasticbreastcancerasingleinstitutionretrospectivestudy AT marillypalettas assessmentofoutcomesandnovelimmunebiomarkersinmetaplasticbreastcancerasingleinstitutionretrospectivestudy AT juliestephens assessmentofoutcomesandnovelimmunebiomarkersinmetaplasticbreastcancerasingleinstitutionretrospectivestudy AT josephliu assessmentofoutcomesandnovelimmunebiomarkersinmetaplasticbreastcancerasingleinstitutionretrospectivestudy AT amandaluff assessmentofoutcomesandnovelimmunebiomarkersinmetaplasticbreastcancerasingleinstitutionretrospectivestudy AT bhuvaneswariramaswamy assessmentofoutcomesandnovelimmunebiomarkersinmetaplasticbreastcancerasingleinstitutionretrospectivestudy AT maryamlustberg assessmentofoutcomesandnovelimmunebiomarkersinmetaplasticbreastcancerasingleinstitutionretrospectivestudy |